文献速递创伤骨科骨质疏松与代谢性骨病

质子泵抑制剂与髋部骨折风险:观察性研究的荟萃分析

Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies.
PubMed 文献 · Osteoporos Int · 2018-12-12

该荟萃分析纳入24项观察性研究共2,103,800名参与者(其中髋部骨折患者319,568例),评估质子泵抑制剂(PPI)与髋部骨折风险的关联。结果显示,使用PPI者髋部骨折风险高于未使用者(RR 1.20,95% CI 1.14-1.28,p<0.0001),且高剂量、长期治疗者关联更强;H2受体拮抗剂(H2RA)暴露未见此关联。作者建议医生对已有髋部骨折高风险的患者考虑长期PPI治疗时应谨慎,患者应关注PPI的不当使用。

要点

  • 使用PPI者髋部骨折风险高于未使用者(RR 1.20,95% CI 1.14-1.28,p<0.0001)。
  • 低、中、高剂量PPI均与髋部骨折风险升高相关,高剂量者关联更强(RR 1.30,95% CI 1.20-1.40,p<0.0001)。
  • 短期和长期PPI治疗者相比未使用者,合并风险比分别为1.20(95% CI 1.15-1.25)和1.24(95% CI 1.10-1.40)。

核心结论

  • 作者认为PPI使用与髋部骨折风险增加显著相关,而H2RA暴露未观察到该关联。
  • 作者建议医生对已有髋部骨折高风险的患者考虑长期PPI治疗时应谨慎。
  • 作者提出患者应关注PPI的不当使用,如有必要应在明确指征下继续使用。

研究设计与样本

  • 检索MEDLINE、EMBASE、Google Scholar和Web of Science从1990年1月1日至2018年3月31日的文献。
  • 仅纳入样本量≥500、随访至少1年且髋部骨折患者通过标准程序识别的观察性研究。
  • 由两名作者根据标准化方案独立提取每项纳入研究的数据。
  • 最终纳入24项观察性研究,共2,103,800名参与者,其中髋部骨折患者319,568例。

主要发现

  • 使用PPI者髋部骨折风险高于未使用者(RR 1.20,95% CI 1.14-1.28,p<0.0001)。
  • 低剂量PPI与髋部骨折风险升高相关(RR 1.17,95% CI 1.05-1.29,p=0.002)。
  • 中剂量PPI与髋部骨折风险升高相关(RR 1.28,95% CI 1.14-1.44,p<0.0001)。
  • 高剂量PPI与髋部骨折风险的关联更强(RR 1.30,95% CI 1.20-1.40,p<0.0001)。
  • 相比未使用者,短期PPI治疗者合并风险比为1.20(95% CI 1.15-1.25,p<0.0001),长期治疗者为1.24(95% CI 1.10-1.40,p<0.0001)。

临床怎么用

  • 作者建议医生对已有髋部骨折高风险的患者考虑长期PPI治疗时应谨慎。
  • 作者提出患者应关注PPI的不当使用;如有必要,应在明确指征下继续接受PPI治疗。

局限性

  • 作者在结论中提出这些结果应谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: We performed a meta-analysis of relevant studies to quantify the magnitude of the association between proton pump inhibitors (PPIs) and risk of hip fracture. Patients with PPIs had a greater risk of hip fracture than those without PPI therapy (RR 1.20, 95% CI 1.14-1.28, p < 0.0001). These results could be taken into consideration with caution, and patients should also be concerned about the inappropriate use of PPIs. INTRODUCTION: Proton pump inhibitors (PPIs) are generally considered as first-line medicine with great safety profile, commonly prescribed for gastroesophageal reflux disease (GERD) and peptic ulcer disease. However, several epidemiological studies documented that long-term use of PPIs may be associated with an increased risk of hip fracture. Although, the optimal magnitude of the hip fracture risk is still undetermined. We, therefore, performed a meta-analysis of relevant studies to quantify the magnitude of the association between PPIs and risk of hip fracture. METHODS: We collected relevant articles using MEDLINE, EMBASE, Google Scholar, and Web of Science from January 1, 1990, to March 31, 2018. We included only the large (n ≥ 500) observational studies with a follow-up duration of at least one year in which the hip fracture patients were identified by a standard procedure. Two of the authors extracted data from each included study independently according to a standardized protocol. RESULTS: A total of 24 observational studies with 2,103,800 participants (319,568 hip fracture patients) met all the eligibility criteria. Patients with PPIs had a greater risk of hip fracture than those without PPI therapy (RR 1.20, 95% CI 1.14-1.28, p < 0.0001). An increased association was also observed in both low and medium doses of PPI taken and hip fracture risk (RR 1.17, 95% CI 1.05-1.29, p = 0.002; RR 1.28, 95% CI 1.14-1.44, p < 0.0001), but it appeared to be even greater among the patients with higher dose (RR 1.30, 95% CI 1.20-1.40, p < 0.0001). Moreover, the overall pooled risk ratios were 1.20 (95% CI 1.15-1.25, p < 0.0001) and 1.24 (95% CI 1.10-1.40, p < 0.0001) for the patients with short- and long-term PPI therapy, respectively, compared with PPI non-users. CONCLUSION: Our results suggest that PPI use is significantly associated with an increased risk of hip fracture development, which is not observed in H2RA exposure. Physicians should, therefore, exercise caution when considering a long-term PPI treatment to their patients who already have an elevated risk of hip fracture. In addition, patients should be concerned about the inappropriate use of PPIs; if necessary, then, they should continue to receive it with a clear indication.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Poly TN, Islam MM, Yang HC, et al. Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies. Osteoporos Int. 2018. PMID: 30539272. doi:10.1007/s00198-018-4788-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。